Study details
Enrolling now
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Diakonos Oncology Corporation
NCT IDNCT04157127ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
18
Study length
about 7.4 years
Ages
18+
Locations
3 sites in TX
What this study is about
This trial is testing a treatment called autologous DC therapy, which uses your own immune cells, in combination with standard chemotherapy for pancreatic cancer. The goal of this phase 1 trial is to determine the safety and feasibility of this new approach.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Autologous DC Therapy
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Overall Survival, Recurrence-Free Survival
Body systems
Oncology